STING1 and cancer: DNA or CDNs from dying cancer cells can trigger STING signaling to induce antigen presentation activity, type I IFN signaling required for appropriate T cell priming by antigen-presenting cells (APCs), costimulatory ligand expression on APCs, and chemokines (e.g., CXCL9 and CXCL10) that enable T cell trafficking to the tumor site (8).